Author:
Cipriani Andrea,Ioannidis John P A,Rothwell Peter M,Glasziou Paul,Li Tianjing,Hernandez Adrian F,Tomlinson Anneka,Simes John,Naci Huseyin
Funder
National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre
Reference124 articles.
1. Vioxx, the implosion of Merck, and aftershocks at the FDA;Horton;Lancet,2004
2. Failing the public health—rofecoxib, Merck, and the FDA;Topol;N Engl J Med,2004
3. Risk of cardiovascular events associated with selective COX-2 inhibitors;Mukherjee;JAMA,2001
4. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis;Jüni;Lancet,2004
5. Postmarketing surveillance—lack of vigilance, lack of trust;Fontanarosa;JAMA,2004
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献